Patterns of cholinesterase-inhibitor use in the nursing home setting: A retrospective analysis

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 2, 2006, Pages 154-160

  Dybicz, Sharon B ^a   Keohane, Denis J ^b   Gary Erwin, W ^a   McRae, Thomas ^b   Shah, Sonali N ^b  

^a Omnicare Senior Health Outcomes LLC   (United States)

^b PFIZER INC   (United States)

Author keywords

Alzheimer's disease; donepezil; galantamine; long term care; rivastigmine

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME; NURSING HOME PATIENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; FEMALE; GALANTAMINE; HOMES FOR THE AGED; HUMANS; INDANS; MALE; MIDDLE AGED; NURSING HOMES; PHENYLCARBAMATES; PIPERIDINES; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 33745932853     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.06.002     Document Type: Article

References (22)

1. Small G.W., Rabins P.V., Barry P.P., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278 (1997) 1363-1371
2. National Center for Health Statistics. The National Nursing Home Survey: 1999 Summary. Series 13, no 152 (2002), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, Md
3. O'Brien J.A., and Caro J.J. Alzheimer's disease and other dementia in nursing homes: Levels of management and cost. Int Psychogeriatr 13 (2001) 347-358
4. Hill J.W., Futterman R., Duttagupta S., et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 58 (2002) 62-70
5. Fillit H., and Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 3 (2005) 39-49
6. Burns A., Rossor M., Hecker J., et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999) 237-244
7. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T., and Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 158 (1998) 1021-1031
8. Corey-Bloom J., Anand R., and Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1 (1998) 55-65
9. Winblad B., Engedal K., Soininen H., et al., Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
10. [published correction appears in BMJ 2001;322:1456]. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 318 (1999) 633-638
11. Tariot P.N., Solomon P.R., Morris J.C., et al., Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54 (2000) 2269-2276
12. [published correction appears in BMJ 2001;322: 405]. Wilcock G.K., Lilienfeld S., Gaens E., and Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ 321 (2000) 1445-1449
13. Winblad B., Engedal K., Soininen H., et al. Long-term efficacy of donepezil in patients with mild-to-moderate Alzheimer's disease: Results from a 1-year placebo-controlled study and 2-year follow-up study. Int Psychogeriatr 15 Suppl 2 (2003) 293-294
14. Doody R.S., Geldmacher D.S., Gordon B., et al., Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
15. Raskind M.A., Peskind E.R., Wessel T., Yuan W., and Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
16. Brangman S.A. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care. Am J Alzheimers Dis Other Demen 18 (2003) 79-84
17. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's dis ease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
18. Winblad B., Kilander L., Eriksson S., et al., Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel group, placebo-controlled study. Lancet 367 (2006) 1057-1065
19. Donepezil hydrochloride [package insert] (2003), Eisai Inc, Teaneck, NJ
20. Rivastigmine tartrate [package insert] (2003), Janssen Pharmaceutica Products, LP, Titusville, NJ
21. Galantamine hydrobromide [package insert] (2001), Novartis Pharmaceuticals, East Hanover, NJ
22. Abstract. Shah S.N., Keohane D., Strunk B.D., et al. Retrospective analysis of characteristics in long-term care residents with Alzheimer's disease continuing versus discontinuing donepezil treatment. J Am Geriatr Soc 52 Suppl 1 (2004) S49